+357 96 030922
info@marketpublishers.com

Pediatric Neuroblastoma Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, and Others), By End-User (Hospitals, Specialty Clinics and Others), By Region & Competition, 2020-2030F

https://marketpublishers.com/r/PE86265F1E7AEN.html
Date: March 2025
Pages: 182
Price: US$ 4,500.00 (Single User License)
ID: PE86265F1E7AEN

Abstracts

Global Pediatric Neuroblastoma Treatment Market was valued at USD 1.45 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.58% through 2030. Pediatric Neuroblastoma is a type of cancer that primarily affects young children, usually occurring in infants and toddlers but occasionally in older children. It arises from immature nerve cells (neuroblasts) that are found in various areas of the body, most commonly in the adrenal glands, which sit on top of the kidneys. However, it can also develop in other parts of the sympathetic nervous system, including the chest, abdomen, and pelvis. The symptoms of neuroblastoma vary depending on the tumor's size, location, and whether it has spread. Common symptoms may include abdominal swelling, pain, a lump or mass, weight loss, loss of appetite, bone pain, irritability, fever, and changes in the eyes (such as drooping eyelids or unequal pupil size). Diagnosis often involves a combination of imaging tests, such as ultrasound, CT scans, and MRI scans, to locate and evaluate the tumor. Biopsy and bone marrow aspiration may also be performed to confirm the diagnosis and determine the tumor's aggressiveness. For instance, according to the American Society of Clinical Oncology (ASCO), neuroblastoma is the third most prevalent cancer among children in the U.S., representing 6% of all childhood cancer cases. This high incidence is expected to drive demand for advanced and effective treatment options to improve outcomes for children diagnosed with neuroblastoma.

+357 96 030922
info@marketpublishers.com

Key Market Drivers

Rising Incidence of Pediatric Neuroblastoma

Growing awareness among healthcare providers and the public about the signs and symptoms of pediatric neuroblastoma has led to earlier diagnosis. As more cases are detected at an earlier stage, there is a greater need for timely and effective treatment. For instance, according to a 2025 study titled Global and Regional Trends in Paediatric Neuroblastoma Incidence and Mortality, 1990-2021: An Inequality and Projection Analysis, the global age-standardized death rate for pediatric neuroblastoma increased from 0.19 (95% UI, 0.16-0.23) in 1990 to 0.21 (95% UI, 0.14-0.28) per 100,000 population in 2021, with an estimated annual percentage change (EAPC) of 0.2. Regionally, mortality and incidence rates were highest in low-to-middle Social Development Index (SDI) regions, while Oceania recorded the lowest rates. Improved diagnostic techniques, such as genetic testing and advanced imaging, have made it easier to identify neuroblastoma cases accurately. This early detection allows for prompt intervention and treatment. The general growth in the global population, including the pediatric population, naturally leads to an increase in the number of neuroblastoma cases. While the exact causes of neuroblastoma remain unclear, some environmental and genetic factors may contribute to its development. As these factors continue to be studied, it may become possible to identify at-risk populations more effectively. The rising incidence of neuroblastoma has prompted increased research into potential treatments. Clinical trials and research efforts are essential in developing new therapies, which, in turn, drive the demand for Pediatric Neuroblastoma Treatment. The development of more effective and less toxic treatment options has improved the chances of successful outcomes for neuroblastoma patients. This has increased the demand for these treatments as they become more accessible. Advances in supportive care for pediatric cancer patients have improved overall treatment experiences and outcomes. As the quality of care continues to improve, more families seek treatment for their children. Improved access to healthcare services in various regions around the world means that more children with neuroblastoma are receiving appropriate treatment. This factor will help in the development of the Global Pediatric Neuroblastoma Treatment Market.

Key Market Challenges

Toxicity and Long-Term Effects

The standard treatments for pediatric neuroblastoma, which often include

+357 96 030922
info@marketpublishers.com

chemotherapy, radiation therapy, and surgery, can cause severe side effects in young patients. These treatments may damage healthy tissues and organs in addition to targeting cancer cells. The toxicity can result in short-term complications, such as nausea, fatigue, and hair loss, which can significantly impact a child's quality of life during treatment. Beyond the immediate treatment period, pediatric neuroblastoma survivors may face long-term health issues and late effects of treatment. These can include developmental delays, growth problems, hormonal imbalances, organ dysfunction, and an increased risk of secondary cancers. Monitoring and managing these long-term health issues require ongoing medical care and support. The toxicity and long-term effects of treatment can affect a child's physical and emotional well-being, as well as their ability to engage in normal childhood activities. This can have a lasting impact on their quality of life and overall development. Pediatric neuroblastoma and its treatment can take a toll on the psychological well-being of both patients and their families. Coping with treatment-related toxicity and long-term effects can be emotionally challenging, requiring psychosocial support and mental health services. Pediatric neuroblastoma survivors often require specialized survivorship care to address the unique health issues that may arise years after treatment. Access to comprehensive follow-up care and support services is essential to managing these long-term effects effectively. Finding the right balance between delivering effective treatment and minimizing toxicity is a complex challenge in pediatric neuroblastoma care. Oncologists must make treatment decisions that maximize the chances of a cure while minimizing potential harm.

Key Market Trends

Minimizing Radiation

Radiation therapy, while effective in treating neuroblastoma, can cause long-term side effects, especially in pediatric patients. These side effects may include growth abnormalities, developmental delays, and an increased risk of secondary cancers. Minimizing radiation aims to mitigate these risks. Innovations in radiation therapy techniques, such as intensity-modulated radiation therapy (IMRT) and proton therapy, allow for more precise targeting of cancer cells while sparing nearby healthy tissues. This precision reduces the potential for collateral damage and long-term toxicity. Radiation oncologists are increasingly tailoring treatment plans to each patient's specific needs and tumor characteristics. This individualized approach ensures that the minimum necessary radiation dose is used while maximizing therapeutic benefits. Minimizing radiation is often achieved through combination therapies. For instance, using chemotherapy or surgery to shrink tumors before radiation may allow for lower

+357 96 030922
info@marketpublishers.com

radiation doses and less toxicity. Risk stratification of neuroblastoma patients helps determine the appropriate level of treatment intensity. Low-risk patients may receive less aggressive therapy, including reduced radiation, to minimize long-term effects. Ongoing clinical trials are exploring novel treatment approaches that may reduce the reliance on radiation therapy or allow for lower radiation doses. These trials aim to maintain or improve treatment outcomes while minimizing toxicity. As more children with neuroblastoma survive into adulthood, there is a growing emphasis on long-term survivorship care. Minimizing radiation plays a role in reducing the late effects of treatment and improving the quality of life for survivors.

Key Market Players

United Therapeutics Corporation

APEIRON Biologics AG

Baxter International Inc.

Cell Ectar Biosciences Inc.

Pfizer Inc.

Bayer AG

Provectus Biopharmaceuticals Inc.

Sartorius AG

Amgen Inc.

F. Hoffmann-La Roche AG

Report Scope:

In this report, the Global Pediatric Neuroblastoma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

+357 96 030922
info@marketpublishers.com

Pediatric Neuroblastoma Treatment Market, By Treatment Type:

Chemotherapy

Immunotherapy

Radiation Therapy

Others

Pediatric Neuroblastoma Treatment Market, By End-User:

Hospitals

Specialty clinics

Others

Pediatric Neuroblastoma Treatment Market, By region:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

South Korea

Australia

Japan

+357 96 030922
info@marketpublishers.com

Europe

Germany

France

United Kingdom

Spain

Italy

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Neuroblastoma Treatment Market.

Available Customizations:

Global Pediatric Neuroblastoma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The

+357 96 030922
info@marketpublishers.com

following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

6. ASIA PACIFIC PEDIATRIC NEUROBLASTOMA TREATMENT MARKET OUTLOOK

+357 96 030922
info@marketpublishers.com

7. EUROPE PEDIATRIC NEUROBLASTOMA TREATMENT MARKET OUTLOOK

+357 96 030922
info@marketpublishers.com

8. NORTH AMERICA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET OUTLOOK

9. SOUTH AMERICA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET OUTLOOK

+357 96 030922
info@marketpublishers.com

10. MIDDLE EAST AND AFRICA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET OUTLOOK

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

16. COMPETITIVE LANDSCAPE

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Pediatric Neuroblastoma Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, and Others), By End-User (Hospitals, Specialty Clinics and Others), By Region & Competition, 2020-2030F

Product link: https://marketpublishers.com/r/PE86265F1E7AEN.html

Price: US$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/PE86265F1E7AEN.html